Table 5 Glass’s ∆ effect size of interventions with respect to the control for muscle and liver acylcarnitines (*small effect (∆ ≥ 0.2), **moderate effect (∆ ≥ 0.5), ***large effect (∆ ≥ 0.8)).
Measurement | Cohort | |||
|---|---|---|---|---|
CR1(N = 7) | CR2(N = 7) | EX1(N = 7) | EX2(N = 7) | |
Liver AC C0 | 0.72** | 0.72** | 0.51** | 0.44* |
Liver AC C2 | −0.08 | 0.11 | 0.60** | −0.13 |
Liver AC C16:0 | 0.43* | −0.02 | 0.96*** | 0.33* |
Liver AC C18:0 | 0.28* | −0.01 | 2.20*** | 1.11*** |
Liver AC C18:1 | 0.40* | −0.05 | 1.51*** | 0.68** |
Muscle AC C0 | 0.77** | 0.65** | 1.20*** | 0.45* |
Muscle AC C2 | 0.04 | −0.25* | 0.05 | −0.56** |
Muscle AC C4-OH | −0.45* | −0.60** | −0.20* | −1.00*** |
Muscle AC C16:0 | 0.42* | 0.01 | 0.15 | 0.52** |
Muscle AC C18:0 | 0.47* | 0.30* | 0.22* | 0.72** |
Muscle AC C18:1 | 0.40* | −0.01 | 0.21* | 0.40* |